Phase 3 HIMALAYA Trial Shows OS Benefit of Durvalumab in HCC
Milind Javle, MD, discusses the phase 3 HIMALAYA study of durvalumab and tremelimumab in patients with locally advanced or metastatic hepatocellular cancer.
Addition of Durvalumab Improves OS for Advanced BTC
Milind Javle, MD, discusses the use of durvalumab for locally advanced or metastatic biliary tract cancer.
Key Takeaways for the Treatment of Cholangiocarcinoma
Concluding his reflection on novel therapies in patients with cholangiocarcinoma, Milind Javle, MD, provides closing thoughts and practical advice for his community colleagues.
Recent Changes in the Cholangiocarcinoma Treatment Landscape
Dr Milind Javle discusses novel therapies recently approved or under investigation across multiple lines of therapy in patients with cholangiocarcinoma.
Metastatic Cholangiocarcinoma: Phase 2 Infigratinib Study and Personal Experience With Infigratinib
Milind Javle, MD, shares his personal experience and insights on the approval and use of infigratinib, an FGFR2 fusion–targeted therapy, in patients with previously treated advanced cholangiocarcinoma.
Treatment Options for Metastatic Cholangiocarcinoma
Oncologist Dr. Milind Javel provides an overview of first- and subsequent-line treatments for patients with cholangiocarcinoma.
Diagnosing Cholangiocarcinoma: Challenges and Molecular Profiling
Dr Milind Javle discusses challenges that exist in the early identification of cholangiocarcinoma, as well as the benefits of comprehensive molecular profiling.
Case Review: A 61-Year-Old Woman With Metastatic Cholangiocarcinoma
Expert oncologist Milind Javle, MD, reviews the diagnosis and treatment of intrahepatic cholangiocarcinoma in a 61-year-old who presents with jaundice and changes in stool and urine color.
2 Commerce Drive Cranbury, NJ 08512